Trial
NCT06670105
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
Genentech, Inc.
Condition
B-cell Lymphoma
Intervention
Glofitamab
Why stopped
PI Request
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-17